EGFR and non-small cell lung carcinoma: These observations are consistent with those of previous studies; Kaira et al. reported that long‐term survivors of more than five years (patients with pretreated NSCLC) might require treatment with not only EGFR‐TKI but also repeated cytotoxic agents.38 Similarly, Huang et al. reported that EGFR‐TKI treatment duration of more than one year plays an important role in long‐term survival.39